Literature DB >> 27959676

Drugging the Undruggable Ras - Immunotherapy to the Rescue?

Carl H June1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 27959676     DOI： 10.1056/NEJMe1612215

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  7 in total

1.  Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.

Authors:  Qingyuan Huang; Hua Zhang; Josephine Hai; Mark A Socinski; Eric Lim; Haiquan Chen; Justin Stebbing
Journal:  Oncoimmunology       Date:  2018-06-20       Impact factor: 8.110

2.  Precancer Atlas to Drive Precision Prevention Trials.

Authors:  Avrum Spira; Matthew B Yurgelun; Ludmil Alexandrov; Anjana Rao; Rafael Bejar; Kornelia Polyak; Marios Giannakis; Ali Shilatifard; Olivera J Finn; Madhav Dhodapkar; Neil E Kay; Esteban Braggio; Eduardo Vilar; Sarah A Mazzilli; Timothy R Rebbeck; Judy E Garber; Victor E Velculescu; Mary L Disis; Douglas C Wallace; Scott M Lippman
Journal:  Cancer Res       Date:  2017-04-01       Impact factor: 13.312

3.  Deubiquitinase inhibitor degrasyn suppresses metastasis by targeting USP5-WT1-E-cadherin signalling pathway in pancreatic ductal adenocarcinoma.

Authors:  Jiajia Li; Haiying Li; Weijian Zhu; Bin Zhou; Jianchao Ying; Jiansheng Wu; Huxiang Zhang; Hongwei Sun; Shenmeng Gao
Journal:  J Cell Mol Med       Date:  2019-12-17       Impact factor: 5.310

Review 4.  Glycogen Synthase Kinase 3β in Cancer Biology and Treatment.

Authors:  Takahiro Domoto; Masahiro Uehara; Dilireba Bolidong; Toshinari Minamoto
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

5.  Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.

Authors:  Peng Bai; Yongzheng Li; Qiuping Zhou; Jiaqi Xia; Peng-Cheng Wei; Hexiang Deng; Min Wu; Sanny K Chan; John W Kappler; Yu Zhou; Eric Tran; Philippa Marrack; Lei Yin
Journal:  Oncoimmunology       Date:  2021-01-15       Impact factor: 8.110

6.  Development of a single-chain fragment variable fused-mutant HALT-1 recombinant immunotoxin against G12V mutated KRAS colorectal cancer cells.

Authors:  Michelle Yee Mun Teo; Jeremy Jeack Ceen Ng; Jung Yin Fong; Jung Shan Hwang; Adelene Ai-Lian Song; Renee Lay Hong Lim; Lionel Lian Aun In
Journal:  PeerJ       Date:  2021-04-15       Impact factor: 2.984

Review 7.  T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy.

Authors:  Malcolm J W Sim; Peter D Sun
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.